{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-23-000035","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.596592+00:00","generated_at":"2026-06-15T01:40:30.082283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mineralys Q1 net loss $12.6M from $7.6M YoY; cash $301.8M; Lorundrostat pivotal trial dosed","bullets":["Net loss $12.6M vs $7.6M in Q1 2022; R&D expense $12.3M (up from $6.8M) driven by $4.0M milestone payment to Mitsubishi Tanabe.","Cash, equivalents & investments $301.8M as of Mar 31, 2023, up from $110.1M; expected to fund operations through mid-2025.","Initiated Advance-HTN Phase 2 pivotal trial (lorundrostat) in April 2023; topline data expected H1 2024.","Plans to initiate Launch-HTN Phase 3 (H2 2023) and a CKD Phase 2 trial (mid-2023); Launch-HTN data expected mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-23-000035","json":"https://secwatch.observer/filing/0001933414-23-000035.json","markdown":"https://secwatch.observer/filing/0001933414-23-000035.md","text":"https://secwatch.observer/filing/0001933414-23-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/0001933414-23-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/mlys-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:40:30.082283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41cf99097147fb9521b536cb8b7848c644e78107","claim":"Mineralys Therapeutics, Inc. reported first quarter 2023 results: net income $12.6 million.","evidence_excerpt":"Net loss was $12.6 million for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/0001933414-23-000035-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Net income","value":"$12.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}